High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma (Q50487052)

14 March 2018

title

High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma (English)

1 reference

14 March 2018

1 reference

14 March 2018

Penelope M Webb

0 references

Diether Lambrechts

1 reference

14 March 2018

Lars A Akslen

1 reference

14 March 2018

Ignace Vergote

1 reference

14 March 2018

Frédéric Amant

Frédéric Amant

1 reference

14 March 2018

Helga Salvesen

Helga B Salvesen

1 reference

14 March 2018

Philippe Moerman

Philippe Moerman

1 reference

14 March 2018

Ingrid Vandenput

Ingrid Vandenput

1 reference

14 March 2018

author name string

Diego A Garcia-Dios

1 reference

14 March 2018

Lieve Coenegrachts

1 reference

14 March 2018

An Capoen

1 reference

14 March 2018

Kaltin Ferguson

1 reference

14 March 2018

ANECS

1 reference

14 March 2018

Bart Claes

1 reference

14 March 2018

Johan Van Robays

1 reference

14 March 2018

Janusz Marcickiewicz

1 reference

14 March 2018

language of work or name

English

0 references

publication date

4 December 2012

1 reference

14 March 2018

published in

Gynecologic Oncology

1 reference

14 March 2018

volume

128

1 reference

14 March 2018

issue

1 reference

14 March 2018

page(s)

327-334

1 reference

14 March 2018

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Emerging therapeutic targets in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Mucinous histology is a risk factor for nodal metastases in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Cancer-specific mutations in PIK3CA are oncogenic in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Rare cancer-specific mutations in PIK3CA show gain of function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Mutational Analysis of thePTENGene in Endometrial Carcinoma and Hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.037

10.1016/J.YGYNO.2012.11.037

7 January 2021

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018